Gap junctions support the sustained phase of hypoxic pulmonary vasoconstriction by facilitating calcium sensitization

Cardiovasc Res. 2013 Aug 1;99(3):404-11. doi: 10.1093/cvr/cvt129. Epub 2013 May 25.

Abstract

Aims: To determine the role of gap junctions (GJs) in hypoxic pulmonary vasoconstriction (HPV).

Methods and results: Studies were performed in rat isolated intrapulmonary arteries (IPAs) mounted on a myograph and in anaesthetized rats. Hypoxia induced a biphasic HPV response in IPAs preconstricted with prostaglandin F2α (PGF2α, 3 µM) or 20 mM K⁺. The GJ inhibitors 18β-glycyrrhetinic acid (18β-GA, 30 µM), heptanol (3.5 mM), or 2-aminoethoxydiphenyl borate (2-APB) (75 µM) had little effect on the transient Phase 1 of HPV, but abolished the sustained Phase 2 which is associated with Ca²⁺ sensitization. The voltage-dependent Ca²⁺ channel blocker diltiazem (10 µM) had no effect on HPV, and did not alter the inhibitory action of 18β-GA. Sustained HPV is enhanced by high glucose (15 mM) via potentiation of Ca²⁺ sensitization, in the presence of high glucose 18β-GA still abolished sustained HPV. Simultaneous measurement of tension and intracellular Ca²⁺ using Fura PE-3 demonstrated that whilst 18β-GA abolished tension development during sustained HPV, it did not affect the elevation of intracellular Ca²⁺. Consistent with this, 18β-GA abolished hypoxia-induced phosphorylation of the Rho kinase target MYPT-1. In anaesthetized rats hypoxia caused a biphasic increase in systolic right ventricular pressure. Treatment with oral 18β-GA (25 mg/kg) abolished the sustained component of the hypoxic pressor response.

Conclusion: These results imply that GJs are critically involved in the signalling pathways leading to Rho kinase-dependent Ca²⁺ sensitization during sustained HPV, but not elevation of intracellular Ca²⁺, and may explain the dependence of the former on an intact endothelium.

Keywords: 18β-glycyrrhetinic acid; Ca2+ sensitization; Gap junctions; Hypoxic pulmonary vasoconstriction; Pulmonary artery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / metabolism
  • Diltiazem / pharmacology
  • Gap Junctions / drug effects
  • Gap Junctions / metabolism*
  • Glycyrrhetinic Acid / analogs & derivatives
  • Glycyrrhetinic Acid / pharmacology
  • Hypoxia / metabolism
  • Hypoxia / physiopathology*
  • Male
  • Phosphorylation
  • Protein Phosphatase 1 / metabolism
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / metabolism
  • Pulmonary Artery / physiopathology*
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology*
  • rho-Associated Kinases / metabolism

Substances

  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • 18alpha-glycyrrhetinic acid
  • rho-Associated Kinases
  • Ppp1r12a protein, rat
  • Protein Phosphatase 1
  • Diltiazem
  • Glycyrrhetinic Acid
  • Calcium